Immuneering (IMRX)
(Delayed Data from NSDQ)
$3.21 USD
+0.79 (32.64%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $3.22 +0.01 (0.31%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
IMRX 3.21 +0.79(32.64%)
Will IMRX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for IMRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IMRX
IMRX Stock Soars on Upbeat Efficacy Data From Pancreatic Cancer Study
Immuneering (IMRX) Plummets 71% in One Week: Here's Why
IMRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Think Immuneering Corporation (IMRX) Could Surge 103.8%: Read This Before Placing a Bet
Immuneering Corporation (IMRX) Reports Q1 Loss, Misses Revenue Estimates
Morphic Holding, Inc. (MORF) Moves 22.5% Higher: Will This Strength Last?
Other News for IMRX
Wall Street Breakfast: The Week Ahead
Catalyst Watch: Spotlight on Micron, Southwest Airlines, and FOMC speakers
Wall Street Analysts Are Bullish on Top Healthcare Picks
3 Penny Stocks to Watch Now, 9/18/24
Outperform Rating Reaffirmed for Immuneering’s Stock Amidst Promising IMM-1-104 Phase 2a Study Results